CN114901689A - 用ilt-2抑制剂治疗癌症 - Google Patents

用ilt-2抑制剂治疗癌症 Download PDF

Info

Publication number
CN114901689A
CN114901689A CN202080069390.1A CN202080069390A CN114901689A CN 114901689 A CN114901689 A CN 114901689A CN 202080069390 A CN202080069390 A CN 202080069390A CN 114901689 A CN114901689 A CN 114901689A
Authority
CN
China
Prior art keywords
antibody
ser
leu
pro
ilt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080069390.1A
Other languages
English (en)
Chinese (zh)
Inventor
O·贝纳克
S·尚特克斯
I·佩罗特
B·罗西
N·维奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of CN114901689A publication Critical patent/CN114901689A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202080069390.1A 2019-10-14 2020-10-13 用ilt-2抑制剂治疗癌症 Pending CN114901689A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914595P 2019-10-14 2019-10-14
US62/914,595 2019-10-14
PCT/EP2020/078792 WO2021074157A1 (en) 2019-10-14 2020-10-13 Treatment of cancer with ilt-2 inhibitors

Publications (1)

Publication Number Publication Date
CN114901689A true CN114901689A (zh) 2022-08-12

Family

ID=72944114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080069390.1A Pending CN114901689A (zh) 2019-10-14 2020-10-13 用ilt-2抑制剂治疗癌症

Country Status (5)

Country Link
US (1) US20240294634A1 (https=)
EP (1) EP4045535A1 (https=)
JP (1) JP2022553927A (https=)
CN (1) CN114901689A (https=)
WO (1) WO2021074157A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7284256B2 (ja) 2019-08-12 2023-05-30 ビオンド バイオロジクス リミテッド Ｉｌｔ２に対する抗体およびその使用
JP2023537396A (ja) 2020-08-12 2023-08-31 ビオンド バイオロジクス リミテッド Ｉｌｔ２に対する抗体およびその使用
WO2024140820A1 (zh) * 2022-12-28 2024-07-04 浙江博锐生物制药有限公司 抗nkg2a抗体及其用途
WO2024260384A1 (en) * 2023-06-20 2024-12-26 Elpiscience (Suzhou) Biopharma, Ltd. Antibodies or antigen-binding fragments binding to lilrb1 and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073116A (zh) * 2014-10-23 2017-08-18 依奈特制药公司 使用抗nkg2a试剂治疗癌症
CN108884163A (zh) * 2016-01-21 2018-11-23 依奈特制药公司 对淋巴细胞中抑制途径的中和
CN113330033A (zh) * 2018-12-26 2021-08-31 先天制药公司 白细胞免疫球蛋白样受体2中和性抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111867614A (zh) * 2018-01-18 2020-10-30 艾达奈特公司 抗lilrb抗体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073116A (zh) * 2014-10-23 2017-08-18 依奈特制药公司 使用抗nkg2a试剂治疗癌症
CN108884163A (zh) * 2016-01-21 2018-11-23 依奈特制药公司 对淋巴细胞中抑制途径的中和
CN113330033A (zh) * 2018-12-26 2021-08-31 先天制药公司 白细胞免疫球蛋白样受体2中和性抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GODAL R等: "Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade", BIOL BLOOD MARROW TRANSPLANT, vol. 16, no. 5, 6 February 2010 (2010-02-06), pages 1 *

Also Published As

Publication number Publication date
WO2021074157A1 (en) 2021-04-22
JP2022553927A (ja) 2022-12-27
EP4045535A1 (en) 2022-08-24
US20240294634A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
US20230235060A1 (en) Neutralization of inhibitory pathways in lymphocytes
CN113330033B (zh) 白细胞免疫球蛋白样受体2中和性抗体
CN108883173B (zh) 抗体和其使用方法
WO2022256563A1 (en) Anti-ccr8 antibodies and uses thereof
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
CN112566935A (zh) 抗ox40抗体和使用方法
CN111465614A (zh) 使用人siglec-9抗体和人nkg2a抗体治疗癌症的组合疗法
CN112513080A (zh) Vista抗原结合分子
JP2019506391A (ja) リンパ球における阻害経路の中和
CN114478769B (zh) 抗tigit抗体、其药物组合物及用途
US20240294634A1 (en) Treatment of cancer with ilt-2 inhibitors
CN114641500A (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
HK40110316A (en) Neutralization of inhibitory pathways in lymphocytes
HK40074321A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220812

WD01 Invention patent application deemed withdrawn after publication